Pancreatic Cancer Research

ResearcherUniversity of Electronic Science and Technology of ChinaNo recent work listed

Ying Deng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2211-0529; OpenAlex author ID A5101668847. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
3
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper

Papers 2

  1. Ginsenoside Rg3 increases gemcitabine sensitivity of pancreatic adenocarcinoma via reducing ZFP91 mediated TSPYL2 destabilization. Last author DOI 10.1016/j.jgr.2021.08.004↗
  2. PLA2G16 is a mutant p53/KLF5 transcriptional target and promotes glycolysis of pancreatic cancer. Co-author DOI 10.1111/jcmm.15832↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Haixia Pan · 1 shared paper, 2022 · strength 0.20
  2. Yi Yang · 1 shared paper, 2020 · strength 0.16
  3. Wei Xia · 1 shared paper, 2020 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.